<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271229</url>
  </required_header>
  <id_info>
    <org_study_id>15-008718</org_study_id>
    <nct_id>NCT03271229</nct_id>
  </id_info>
  <brief_title>Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Single-Blinded, Controlled Trial Comparing Conventional Platelet Rich Plasma (PRP) to Concentrated Bone Marrow Aspirate (BMAC) for Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous clinical trials have demonstrated the human body's own healing and regenerative&#xD;
      cells can relieve the pain of arthritis. Bone marrow contains stem cells which can change&#xD;
      into cells of various different tissue types, while platelet rich plasma contains growth&#xD;
      factors. Both techniques have been shown to relieve pain and with this study the&#xD;
      Investigators wish to compare the two treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized into two groups. Concentrated Bone Marrow Aspirate (BMAC) or&#xD;
      Platelet-Rich Plasma (PRP). BMAC subjects will have bone marrow aspirated from the subjects&#xD;
      iliac crests and the cellular rich portion will be concentrated and subsequently injected&#xD;
      into the subjects' symptomatic knee. BMAC patients will also have a venous whole blood drawn&#xD;
      from the antecubital vein to simulate a PRP procedure. PRP subjects will have the same venous&#xD;
      blood draw from the antecubital vein with subsequent platelet concentration. The resulting&#xD;
      PRP will be injected into the symptomatic knee. PRP subjects will also undergo a bone marrow&#xD;
      aspiration from the iliac crest to simulate the BMAC procedure. Follow-up at 1 week, 6 weeks,&#xD;
      6 months, and 12 months after injection, with repeat radiographs at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>The number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>The number of deceased participants</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Stem Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Concentrated Bone Marrow Aspirate (BMAC)</intervention_name>
    <description>Participants will have a knee injected with BMAC stem cells harvested from the iliac crest</description>
    <arm_group_label>Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet-Rich Plasma (PRP)</intervention_name>
    <description>Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.</description>
    <arm_group_label>Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have bilateral OA and pain in one knee.&#xD;
&#xD;
          -  Osteoarthritis may be primary or secondary. Knees must have Kellgren-Lawrence Grades&#xD;
             1-3.&#xD;
&#xD;
          -  Subjects must have previously tried 6 weeks of one of the following conservative&#xD;
             treatments: Activity modification, weight loss, physical therapy, anti-inflammatory,&#xD;
             or injection therapy.&#xD;
&#xD;
          -  Patients must be able to provide written informed consent after the nature of the&#xD;
             study is fully explained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with abnormal hematology, serum chemistry, or screening laboratory results.&#xD;
&#xD;
          -  Patients taking anti-inflammatory medications (prescription or over-the-counter),&#xD;
             including herbal therapies, within 14 days of baseline visit.&#xD;
&#xD;
          -  Patients taking anti-rheumatic disease medication (including methotrexate or other&#xD;
             antimetabolites) within the 3 months prior to study entry.&#xD;
&#xD;
          -  Patients receiving injections to the treated knee within 3 months prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Patients who are pregnant or currently breast-feeding.&#xD;
&#xD;
          -  Patients with systemic, rheumatic, or inflammatory disease of the knee or&#xD;
             chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee&#xD;
             associated with juxta-articular Paget's disease of the femur or tibia, ochronosis,&#xD;
             hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular&#xD;
             synovitis, and synovial chondromatosis.&#xD;
&#xD;
          -  Patients with ongoing known infectious disease.&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular, renal, hepatic, endocrine&#xD;
             disease, or cancer.&#xD;
&#xD;
          -  Patients participating in a study of an experimental drug or medical device within 30&#xD;
             days of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane A Shapiro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Shane A. Shapiro</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Platelet rich plasma</keyword>
  <keyword>bone marrow</keyword>
  <keyword>stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

